September 10, 2024

Alzheimer's Disease Risk: Novel X Chromosome Loci Identified

Does the X chromosome play a role in the genetics of Alzheimer's disease? A recent meta-analysis investigated.

Conexiant

September 10, 2024

FDA Grants Rare Pediatric Designation to Duchenne Drug

NS-050/NCNP-03 received rare pediatric disease designation for Duchenne muscular dystrophy.

Conexiant

September 01, 2024

Anti-complement Injections for Geographic Atrophy: A Look at the Patient and Provider Experience in my Clinic

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

August 30, 2024

Feds Bolster Health Care Nondiscrimination Protections

HHS issued two final rules strengthening health care nondiscrimination protections, requiring providers to ensure accessibility, mitigate bias in AI tools, and provide language assistance services.

Conexiant

August 26, 2024

FDA Approves IDH1/2 Inhibitor for Certain Patients With Astrocytoma or Oligodendroglioma

The approval is the first by the FDA of a systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.

The ASCO Post

August 21, 2024

Lancet Report: 14 Keys to Dementia Prevention

Lancet Commission identifies 14 modifiable risk factors contributing to 45% of dementia cases.

Conexiant

August 20, 2024

Tinnitus Treatment Combining Sound, Tongue Stimulation Found Effective

Positive outcomes from the TENT-A3 study led to FDA de novo approval of the Lenire device for tinnitus treatment.

Conexiant

August 12, 2024

Organ Damage More Common in Early Stages of Lupus

A recent study sheds light on the impact of early cardiovascular damage in patients with systemic lupus erythematosus, highlighting the need for aggressive early intervention to prevent long-term organ damage.

Conexiant

July 25, 2023

Origins of Glioma Brain Cancer Found to be in the Epigenome

While cancers often originate from mutations and other alterations of cells' DNA, researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas – incurable brain tumors – can arise due to changes in the epigenome, the collection of compounds that are deposited on DNA and alter gene activity without changing the sequence of DNA itself.

Dana-Farber